Vol.40, No.2, Mar. 2013
Dawning of the “Sunshine Act”: Towards a new phase of conflict of interest management
The 2nd International Symposium of Early Stage Clinical Trial / The 31st Aso-Kuju Conference on Clinical Pharmacology
   
Contents
 
EditorialUchida E 236 Full text
 
Dawning of the “Sunshine Act”:
 Towards a new phase of conflict of interest management
 
 Round table discussion: Dawning of the “Sunshine Act”:
  Towards a new phase of conflict of interest management
Uchida E,Miyaoka H,
Imamura K,Iwasaki K
(Organized by Kurihara C)
237-60 Abstract
 Transparency of cooperation between industry and academia and management
  of conflict of interest (COI)-issues involved in “Transparency Guidelines”
Kaku K 261-5 Abstract
 The role of lunch time seminar in lifelong medical educationNango E 267-76 Full text
 Academic information and drug promotional materialsItoh M 277-83 Abstract
 
The 2nd International Symposium of Early Stage Clinical Trial
 Efficient developmental strategy that leads the world
  285-337 Abstract
     Organized by:International Symposium of Early Stage Clinical Trial
     The Head of the Executive Committee:Uchida E
   
 Opening remarksUchida E 287
 How should we proceed with clinical trials in Japan given the global tide
  toward early clinical development?
Kumagai Y 288-95
 Background and progress of pharmacometricsHayashi N 296-301
 Application of pharmacometrics in clinical developmentMiyoshi S 302-7
 Clinical trial unit in Center for Advanced Medical Innovation Kyushu UniversityIkematsu H 308-12
 Early phase clinical trials: Pediatric viewpointNakamura H 313-9
 Clinical development of medical devicesYamamoto H 320-6
 Industry point of viewShishido A 327-31
 Plenary discussion  332-5
 Closing remarksUchida E 336
 
The 31st Aso-Kuju Conference on Clinical Pharmacology
 New developments in clinical pharmacology
  339-88 Abstract
     Organizers:Ohashi K,Nomoto M,Sasaguri T,Ieiri I,Nakano S,
            Higuchi S,Yamada K,Hasegawa J,Sendo T
     
 Opening remarksOhashi K 341
 Challenge of academia for drug developmentAkazawa H 342-7
 Clinical development of medical devices: Present situationYamamoto H 348-54
 Proof of concept (POC) in clinical trialsNomoto M 355-8
 Discussion  359-61
 Involvement and interaction of intestinal transporters for drug absorptionTamai I 362-71
 Current status and issues of PGx sampling in JapanUchida E,Tashiro S 372-7
 Searching for disease susceptibility genes using the omics approach:
  A schizophrenia case
Fukumaki Y 378-86
 Closing remarksNomoto M,Ohashi K 387
 
Symposium:
 From “patient-friendly medical interview” to “psychotherapy with healing power”
     
 From “patient-friendly medical interview” to “psychotherapy with healing power”:
  Recommendation of common-sense psychiatry
Saio T 389-94 Full text
 Basics of the medical interview and Objective Structured
  Clinical Examination (OSCE)
Nango E 395-400 Full text
 Acquiring medical interview skills for use in psychiatric practiceHirashima N 401-5 Full text
 Practical sleep and alcohol education for patients with mild depressionIhara H 407-13 Full text
 Medical interview should be more utilized in the training of a psychiatric interviewMiyaoka H 415-7 Full text
 
Original   
 “Cooperative IRB” issues in Japan, United States, Europe, and AsiaKurihara C,Kageyama S 419-34 Full text
 
Forum   
 CDISC as the global standards ─ Does the introduction bring cost increase?Jyono T 435-6
 Talent development in clinical trials and research in the era of global studies
  -Initiation of educational course in pharmaceutical medicine in 2013-
Imamura K 437-40 Full text
 
Instructions for authors [Japanese] & [English]  441-9 Full text
 
Editor's noteKurihara M 451 Full text


Back to Rinsho Hyoka(Clinical Evaluation) home page
Back to Contents